These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 14975942)

  • 1. Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP.
    Sawyer RT; Parsons CE; Fontenot AP; Maier LA; Gillespie MM; Gottschall EB; Silveira L; Newman LS
    Am J Respir Cell Mol Biol; 2004 Jul; 31(1):122-30. PubMed ID: 14975942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells.
    Amicosante M; Berretta F; Franchi A; Rogliani P; Dotti C; Losi M; Dweik R; Saltini C
    Eur Respir J; 2002 Nov; 20(5):1174-8. PubMed ID: 12449171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beryllium-induced TNF-alpha production is transcription-dependent in chronic beryllium disease.
    Sawyer RT; Fontenot AP; Barnes TA; Parsons CE; Tooker BC; Maier LA; Gillespie MM; Gottschall EB; Silveira L; Hagman J; Newman LS
    Am J Respir Cell Mol Biol; 2007 Feb; 36(2):191-200. PubMed ID: 16980557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial IL-10 inhibition of the cell-mediated immune response in chronic beryllium disease.
    Tinkle SS; Kittle LA; Newman LS
    J Immunol; 1999 Sep; 163(5):2747-53. PubMed ID: 10453017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-presentation of beryllium by BAL CD4+ T cells: T cell-T cell interactions and their potential role in chronic beryllium disease.
    Fontenot AP; Edwards DM; Chou YK; Mack DG; LaTocha D; Vandenbark AA; Burrows GG
    Eur J Immunol; 2006 Apr; 36(4):930-9. PubMed ID: 16552706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation pathways implicate anti-HLA-DP and anti-LFA-1 antibodies as lead candidates for intervention in chronic berylliosis.
    Chou YK; Edwards DM; Weinberg AD; Vandenbark AA; Kotzin BL; Fontenot AP; Burrows GG
    J Immunol; 2005 Apr; 174(7):4316-24. PubMed ID: 15778396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF polymorphism and bronchoalveolar lavage cell TNF-alpha levels in chronic beryllium disease and beryllium sensitization.
    Sato H; Silveira L; Fingerlin T; Dockstader K; Gillespie M; Lagan AL; Lympany P; Sawyer RT; du Bois RM; Welsh KI; Maier LA
    J Allergy Clin Immunol; 2007 Mar; 119(3):687-96. PubMed ID: 17208287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease.
    Tinkle SS; Newman LS
    Am J Respir Crit Care Med; 1997 Dec; 156(6):1884-91. PubMed ID: 9412570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the HLA-DP Glu 69 and the TNF-alpha TNF-alpha 2 gene markers in susceptibility to beryllium hypersensitivity.
    Rogliani P; Amicosante M; Berretta F; Dotti C; Bocchino M; O'Donnell KM; Saltini C
    Int J Immunopathol Pharmacol; 2004; 17(2 Suppl):3-10. PubMed ID: 15345185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High beryllium-stimulated TNF-alpha is associated with the -308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease.
    Maier LA; Sawyer RT; Bauer RA; Kittle LA; Lympany P; McGrath D; Dubois R; Daniloff E; Rose CS; Newman LS
    Am J Respir Crit Care Med; 2001 Oct; 164(7):1192-9. PubMed ID: 11673208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beryllium-ferritin: lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease.
    Sawyer RT; Day BJ; Fadok VA; Chiarappa-Zucca M; Maier LA; Fontenot AP; Silveira L; Newman LS
    Am J Respir Cell Mol Biol; 2004 Oct; 31(4):470-7. PubMed ID: 15256386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-4 fails to regulate in vitro beryllium-induced cytokines in berylliosis.
    Maier LA; Sawyer RT; Tinkle SS; Kittle LA; Barker EA; Balkissoon R; Rose C; Newman LS
    Eur Respir J; 2001 Mar; 17(3):403-15. PubMed ID: 11405518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease.
    Fontenot AP; Maier LA
    Trends Immunol; 2005 Oct; 26(10):543-9. PubMed ID: 16099719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and interleukin-6 but not interleukin-1 beta.
    Bost TW; Riches DW; Schumacher B; Carré PC; Khan TZ; Martinez JA; Newman LS
    Am J Respir Cell Mol Biol; 1994 May; 10(5):506-13. PubMed ID: 8179912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beryllium induces IL-2 and IFN-gamma in berylliosis.
    Tinkle SS; Kittle LA; Schumacher BA; Newman LS
    J Immunol; 1997 Jan; 158(1):518-26. PubMed ID: 8977230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansions of T-cell subsets expressing particular T-cell receptor variable regions in chronic beryllium disease.
    Fontenot AP; Kotzin BL; Comment CE; Newman LS
    Am J Respir Cell Mol Biol; 1998 Apr; 18(4):581-9. PubMed ID: 9533947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.
    Fontenot AP; Torres M; Marshall WH; Newman LS; Kotzin BL
    Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12717-22. PubMed ID: 11050177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production.
    Dobis DR; Sawyer RT; Gillespie MM; Newman LS; Maier LA; Day BJ
    Am J Respir Cell Mol Biol; 2010 Oct; 43(4):458-64. PubMed ID: 19901345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.
    Bosè F; Raeli L; Garutti C; Frigerio E; Cozzi A; Crimi M; Caprioli F; Scavelli R; Altomare G; Geginat J; Abrignani S; Reali E
    Clin Immunol; 2011 May; 139(2):164-76. PubMed ID: 21334981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
    Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
    Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.